IL-12 armored CAR T cell therapy targeting EGFRvIII

IL-12 armored CAR T cell therapy targeting EGFRvIII is an investigational fourth-generation chimeric antigen receptor (CAR) T-cell therapy developed by Duke University. It is designed to target epidermal growth factor receptor variant III (EGFRvIII), a tumor-specific antigen frequently overexpressed in glioblastoma (GBM). To overcome the challenges of tumor antigen heterogeneity and the highly immunosuppressive tumor microenvironment (TME) of GBM, these CAR T cells are "armored" to constitutively secrete single-chain interleukin-12 (scIL12). Localized secretion of IL-12 enhances CAR T-cell persistence, reprograms immunosuppressive microglia and macrophages, and recruits endogenous CD8+ T cells to promote antigen spreading, thereby facilitating the clearance of both EGFRvIII-positive and EGFRvIII-negative tumor cells. Preclinical studies in orthotopic GBM mouse models have demonstrated that this therapy can eradicate heterogeneous tumors and eliminate the need for toxic lymphodepletive preconditioning.

Other names

EGFRvIII CAR scIL12EGFRvIII CAR-scIL12IL-12 CARvIIIIL12 CARvIIIIL 12 CARvIIIIL-12-armored EGFRvIII CAR-T cellsIL12-armored EGFRvIII CAR-T cellsIL 12-armored EGFRvIII CAR-T cellssingle-chain IL-12-secreting EGFRvIII CAR-T cells